ArticleClinical cardiology2013
Cost-effectiveness of paclitaxel-coated balloon angioplasty in patients with drug-eluting stent restenosis.
Article in Clinical cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical outcomes of biodegradable polymer drug-eluting stents for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials.Clinical cardiology · 2014Pooled it
- Cost-Effectiveness of Drug-Coated Balloons in the Treatment of Coronary Small Vessel Disease: A Report From the BASKET-SMALL 2 Randomized Controlled Trial.Journal of the American Heart Association · 2025Trial
- Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction.Journal of cardiothoracic surgery · 2021Trial
- Economic implications of intra-aortic balloon support for myocardial infarction with cardiogenic shock: an analysis from the IABP-SHOCK II-trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Trial
- Cost-Effectiveness of Drug-Coated Balloon Angioplasty versus Plain Old Balloon Angioplasty for Arteriovenous Fistula Stenosis.Cardiovascular and interventional radiology · 2023Article
- Diabetic vasculopathy: macro and microvascular injury.Current pathobiology reports · 2020Article
- Drug-eluting stent restenosis treatment: an "old" stent, a "new" balloon or a "newer" scaffold?Journal of thoracic disease · 2016Article
- Paclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health Technology Assessment.Ontario health technology assessment series · 2015Review
- Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis.Clinical research in cardiology : official journal of the German Cardiac Society · 2014Article
- Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group.Clinical research in cardiology : official journal of the German Cardiac Society · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe economic impact of drug-eluting stent (DES) in-stent restenosis (ISR) is substantial, highlighting the need for cost-effective treatment strategies. HYPOTHESIS: Compared to plain old balloon angioplasty (POBA) or repeat DES implantation, drug-coated balloon (DCB) angioplasty is a cost-effective therapy for DES-ISR.
methodsA Markov state-transition model was used to compare DCB angioplasty with POBA and repeat DES implantation. Model input parameters were obtained from the literature, and the cost analysis was conducted from a German healthcare payer's perspective. Extensive sensitivity analyses were performed.
resultsInitial procedure costs amounted to €3488 for DCB angioplasty and to €2782 for POBA. Over a 6-month time horizon, the DCB strategy was less costly (€4028 vs €4169) and more effective in terms of life-years (LYs) gained (0.497 versus 0.489) than POBA. The DES strategy incurred initial costs of €3167 and resulted in 0.494 LYs gained, at total costs of €4101 after a 6-month follow-up. Thus, DCB angioplasty was the least costly and most effective strategy. Base-case results were influenced mostly by initial procedure costs, target lesion revascularization rates, and the costs of dual antiplatelet therapy.
conclusionsDCB angioplasty is a cost-effective treatment option for coronary DES-ISR. The higher initial costs of the DCB strategy compared to POBA or repeat DES implantation are offset by later cost savings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.